uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. The company is headquartered in Amsterdam, the Netherlands.
| Revenue (TTM) | $18.67M |
| Gross Profit (TTM) | $-114.71M |
| EBITDA | $-182.92M |
| Operating Margin | -872.00% |
| Return on Equity | -157.60% |
| Return on Assets | -15.70% |
| Revenue/Share (TTM) | $0.30 |
| Book Value | $4.67 |
| Price-to-Book | 10.41 |
| Price-to-Sales (TTM) | 178.21 |
| EV/Revenue | 140.66 |
| EV/EBITDA | 1.40 |
| Quarterly Earnings Growth (YoY) | -18.20% |
| Quarterly Revenue Growth (YoY) | 11.00% |
| Shares Outstanding | $69.37M |
| Float | $57.52M |
| % Insiders | 1.26% |
| % Institutions | 96.24% |
Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities.
uniQure posts a wider Q2 2026 loss as revenues missed estimates, but regulatory progress for AMT-130 and a cash runway into 2030 keep its pipeline in focus.
uniQure NASDAQ: QURE said it has aligned with the U.S. Food and Drug Administration on a potential accelerated-approval pathway for AMT-130, its investigational gene therapy for Huntington's disease, and remains on track to submit a biologics license application in the third quarter of 2026.
uniQure (QURE) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to a loss of $0.69 per share a year ago.
~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington's disease on track as planned for the third quarter of 2026 ~ ~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~ ~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~ ~ Strengthened financial position with $259 million follow-on offering, extending cash runway into 2030 and funding the anticipated commercial launch of AMT-130 and continued pipeline investment ~ ~ uniQure to host earnings call at 8:30 a.m. ET ~ LEXINGTON, Mass.
~ uniQure to host earnings call on Wednesday, July 29, 2026 at 8:30 a.m. ET ~ ~ uniQure to host earnings call on Wednesday, July 29, 2026 at 8:30 a.m. ET ~
QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business model and CNS pipeline expansion, with AMT-130 at the center.
QURE has soared on renewed AMT-130 optimism, but rich valuation, uneven earnings and pending regulatory milestones keep the gene therapy story balanced.
QURE's AMT-130 is driving investor focus as FDA feedback, a targeted third-quarter 2026 filing and cash into 2029 shape its regulatory outlook.
The semiconductor rotation and memory stock profit taking puts investors in a bind trying to call the top.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on QURE and any ticker you trade — then tracks every position and per-strategy win rate.
